title: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
authors.affiliation: Department of Nephrology, Georges Pompidou European Hospital, Paris, France.
authors.forename: Carlos
authors.initials: C
authors.lastname: Frangié
authors.forename: Carmen
authors.initials: C
authors.lastname: Lefaucheur
authors.forename: Jacques
authors.initials: J
authors.lastname: Medioni
authors.forename: Christian
authors.initials: C
authors.lastname: Jacquot
authors.forename: Garry S
authors.initials: GS
authors.lastname: Hill
authors.forename: Dominique
authors.initials: D
authors.lastname: Nochy
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D013927:Thrombosis / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab